Kimmen Quan1, Philip Sutera1, Karen Xu1, Mark E Bernard2, Steven A Burton1, Rodney E Wegner1, Herbert Zeh3, Nathan Bahary4, Ronald Stoller4, Dwight E Heron5. 1. Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. 2. Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky. 3. Department of Surgical Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. 4. Department of Medical Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. 5. Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania. Electronic address: herond2@upmc.edu.
Abstract
PURPOSE: Stereotactic ablative radiation therapy's (SABR's) great conformity and short duration has become an attractive treatment modality. We report a phase 2 clinical trial to evaluate efficacy and safety of induction chemotherapy (ICT) followed by SABR in patient with borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC). METHODS AND MATERIALS: Patients with biopsy-proven BR or LA PDAC were treated with four 21-day cycles of intravenous gemcitabine and oral capecitabine. Patients were restaged within 4 weeks after ICT by computed tomography and treated by 3-fraction SABR if no metastasis or progressive disease was identified. Patients were restaged 4 weeks following SABR to determine resectability. Tumor response was assessed with carbohydrate antigen 19-9. RESULTS: Thirty-five patients (19 BR/16 LA) were enrolled. The median age was 71.8 years (range, 50.6-81.1). ICT was completed in 91.4% (n = 32) of patients. All patients who completed ICT completed SABR. Of those 32 patients, 34.3% (n = 12: 10 BR, 2 LA) underwent pancreaticoduodenectomy and 11 of 12 (91.7%) received R0 resection. Median overall survival was 18.8, 28.3, and 14.3 months for the entire cohort, BR, and LA, respectively. The 2-year local progression-free survival (LPFS) was 44.9%, 40%, and 52% for the entire cohort, BR, and LA, respectively. For BR patients, multivariate analysis showed surgery was associated with better overall survival and LPFS. One-year LPFS for patients with surgery was 80% and 44% without surgery. Within the 15.4-month follow-up, no grade 3+ toxicity from SABR was observed. No significant quality of life change was observed before and after ICT, SABR, or surgery for BR or LA patients. CONCLUSIONS: This is the first prospective phase 2 study to investigate the feasibility and efficacy of a 12-week gemcitabine/capecitabine ICT followed by SABR for BR or LA PDAC. The results suggest excellent tolerability, high R0 resection rates, and acceptable posttreatment complications.
PURPOSE: Stereotactic ablative radiation therapy's (SABR's) great conformity and short duration has become an attractive treatment modality. We report a phase 2 clinical trial to evaluate efficacy and safety of induction chemotherapy (ICT) followed by SABR in patient with borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC). METHODS AND MATERIALS: Patients with biopsy-proven BR or LA PDAC were treated with four 21-day cycles of intravenous gemcitabine and oral capecitabine. Patients were restaged within 4 weeks after ICT by computed tomography and treated by 3-fraction SABR if no metastasis or progressive disease was identified. Patients were restaged 4 weeks following SABR to determine resectability. Tumor response was assessed with carbohydrate antigen 19-9. RESULTS: Thirty-five patients (19 BR/16 LA) were enrolled. The median age was 71.8 years (range, 50.6-81.1). ICT was completed in 91.4% (n = 32) of patients. All patients who completed ICT completed SABR. Of those 32 patients, 34.3% (n = 12: 10 BR, 2 LA) underwent pancreaticoduodenectomy and 11 of 12 (91.7%) received R0 resection. Median overall survival was 18.8, 28.3, and 14.3 months for the entire cohort, BR, and LA, respectively. The 2-year local progression-free survival (LPFS) was 44.9%, 40%, and 52% for the entire cohort, BR, and LA, respectively. For BR patients, multivariate analysis showed surgery was associated with better overall survival and LPFS. One-year LPFS for patients with surgery was 80% and 44% without surgery. Within the 15.4-month follow-up, no grade 3+ toxicity from SABR was observed. No significant quality of life change was observed before and after ICT, SABR, or surgery for BR or LA patients. CONCLUSIONS: This is the first prospective phase 2 study to investigate the feasibility and efficacy of a 12-week gemcitabine/capecitabine ICT followed by SABR for BR or LA PDAC. The results suggest excellent tolerability, high R0 resection rates, and acceptable posttreatment complications.
Authors: Sung Jun Ma; Lucas M Serra; Austin J Bartl; Hye Ri Han; Fatemeh Fekrmandi; Austin J Iovoli; Kavitha M Prezzano; Gregory M Hermann; Han Yu; Anurag K Singh Journal: J Radiother Pract Date: 2021-04-14
Authors: Mark E Bernard; Philip A Sutera; Nicholas A Iarrobino; Kimmen Quan; Steven A Burton; Nathan Bahary; Melissa Hogg; Amer Zureikat; Dwight E Heron Journal: Adv Radiat Oncol Date: 2018-11-29
Authors: Ramez Kouzy; Joseph Abi Jaoude; Daniel Lin; Nicholas D Nguyen; Molly B El Alam; Ethan B Ludmir; Cullen M Taniguchi Journal: Cancers (Basel) Date: 2020-09-02 Impact factor: 6.639
Authors: Christelle Bouchart; Jean-Luc Engelholm; Jean Closset; Julie Navez; Patrizia Loi; Yeter Gökburun; Thierry De Grez; Laura Mans; Alain Hendlisz; Maria Antonietta Bali; Pierre Eisendrath; Dirk Van Gestel; Matthieu Hein; Luigi Moretti; Jean-Luc Van Laethem Journal: Ther Adv Med Oncol Date: 2021-10-19 Impact factor: 8.168
Authors: Kelly E Henry; Kyeara N Mack; Veronica L Nagle; Mike Cornejo; Adam O Michel; Ian L Fox; Maria Davydova; Thomas R Dilling; Nagavarakishore Pillarsetty; Jason S Lewis Journal: Mol Cancer Ther Date: 2021-08-04 Impact factor: 6.261